FIELD: medicine, pharmaceutics.SUBSTANCE: invention discloses a medicine for treating a patient with rheumatoid arthritis on the basis of an antibody or a fragment thereof that bind the Extra Domain-A (ED-A) isoform of fibronectin. The antibody or fragment thereof contain the domain VH comprising a frame and a number of complementary-determining regions HCDR 1 -3, and the domain VL comprising a frame and a number of complementary-determining regions LCDR 1-3 with the antibody or fragment thereof being conjugated with IL-10. The invention discloses a medicine on the basis of the above antibody or fragment thereof for delivering a molecule conjugated with the antibody or fragment thereof wherein the molecule represents IL-10 to a newly formed vascular tree of the rheumatoid arthritis regions in a patient. There are disclosed method of treating rheumatoid arthritis with using the medicines under the invention, method of delivering IL-10 conjugated with the antibody or fragment thereof to the newly formed vascular tree of the rheumatoid arthritis regions in the patient, as well as a conjugate of the antibody or fragment thereof binding ED-A of fibronectin to interleukine-10. The antibody or fragment thereof may be represented by a diabody, contain one-chain Fv, present a small immunoprotein (SIP).EFFECT: invention provides the successful treatment of rheumatoid arthritis ensured by the selective delivery of biologically active compounds conjugated on the antibody to the disease locations.35 cl, 8 dwg, 2 tblИзобретение раскрывает лекарственное средство для лечения пациента с ревматоидным артритом, на основе антитела или его фрагмента, которые связывают изоформу Экстра-Домен-А (ED-A) фибронектина. Антитело или его фрагмент содержат домен VH, содержащий каркас и набор определяющих комплементарность областей HCDR 1-3, и домен VL, содержащий каркас и набор определяющих комплементарность областей LCDR 1-3, при этом антитело или его фрагмент конъюгированы с IL-10. Изобретени
